NCT01088386
Zyprexa® Relprevv™ Patient Care Program
Enrolling by Invitation
Not specifiedAges 18+ObservationalEli Lilly and Company
~4,000 participants
Updated 2026-01-28 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) events
Measured over Baseline to end of study
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Any patients receiving Zyprexa Relprevv enrolled in Zyprexa Relprevv Patient Care Program
Exclusion
Any patient not receiving Zyprexa Relprevv
What this trial measures
- Incidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) eventsBaseline to end of study